Recombinant growth hormone

Human growth hormone (somatropin)

Somatropin's half-life after subcutaneous injection is 2.0 to 3.8 hours in healthy adults on four US labels, and the app lists about 2.6 hours.1,2,3,4

Strong evidenceGet the app

Level after one dose

Human growth hormone (somatropin) after one dose: 50% at ~2.6 h, 25% at 5.2 h, 12.5% at 7.8 h.

Drawn from the half-life in the app's model, ~2.6 h. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

4%The 13th most tracked compound in Milligram: of people who track compounds in Milligram logged Human growth hormone (somatropin) in the last 90 days.

Schedule

  1. Daily80%
  2. Every other day14%
  3. Twice a week2%
  4. Weekly2%
  5. Less often1%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 2 and 4 IU per dose; the median was 3 IU.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Human growth hormone (somatropin) who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Somatropin is recombinant human growth hormone: the Genotropin label describes a protein of 191 amino acid residues, produced in Escherichia coli by recombinant DNA technology, whose amino acid sequence is "identical to that of human growth hormone of pituitary origin".5 The Genotropin, Humatrope, Norditropin, Omnitrope and Zomacton labels each list growth failure in children and replacement of endogenous growth hormone in adults with growth hormone deficiency among their uses.5,2,1,3,4

The app grades the evidence for somatropin as strong, and that grade is the app's own.

Brooks and Waters of the University of Queensland, writing in Nature Reviews Endocrinology in 2010, state that growth hormone's actions "are mediated via the growth hormone receptor, both directly by tyrosine kinase activation and indirectly by induction of insulin-like growth factor 1 (IGF-1)".10

The Genotropin label states that in adults with growth hormone deficiency, treatment "results in reduced fat mass, increased lean body mass, metabolic alterations that include beneficial changes in lipid metabolism, and normalization of IGF-I concentrations".5

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~2.6 h
Bioavailability
75%
Typical dose
1–6 IU/day
Route
SubQ
Time to peak
~3 h
Table 4.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported on the labels
Half-lifeAbout 2.6 hoursSubcutaneous, healthy adults: 2.0 (0.5) hours on the Norditropin label (apparent terminal, 4 mg dose), 2.3 on Zomacton, 2.5 to 2.8 on Omnitrope, 3.8 (1.4) on Humatrope. Subcutaneous, adults with growth hormone deficiency: 3.0 hours on Genotropin, 7 to 10 on Norditropin.1,3,4,2,5
Bioavailability75% by subcutaneous injection75% after subcutaneous administration on the Humatrope label; approximately 80% in adults with growth hormone deficiency on Genotropin; approximately 70% on Zomacton; "currently not known" on Norditropin.2,5,3,1
Time to peakAbout 3 hoursHealthy adults: about 3.0 hours on Norditropin and about 4.5 hours on Zomacton (both with endogenous growth hormone suppressed), 4.0 hours on Omnitrope, median 4.0 (range 3 to 8) hours on Humatrope. Adults with growth hormone deficiency: 4 to 5 hours on Norditropin, about 6 hours on Genotropin.1,4,3,2,5
Duration of activityAbout 12 hoursNone of the five labels states a duration of action. After a single 4 mg subcutaneous dose in healthy subjects with suppressed endogenous growth hormone, IGF-1 peaked at about 24 hours and was comparable to predose at 96 hours (Norditropin and Zomacton labels); the Humatrope label gives a median IGF-1 peak at 21 hours in men and 14 hours in women after 0.033 mg/kg subcutaneously.

The Genotropin label gives 0.4 hours intravenously against 3.0 hours subcutaneously and states that "The observed difference is due to slow absorption from the subcutaneous injection site".5

The chart below illustrates a one-compartment curve built from the app's half-life of 2.6 hours and time to peak of 3 hours, with the daily interval used in the Genotropin label's adult trials.5

Level over 3 days

Interval between doses

Level, as a share of the peak after one 2 IU dose

As studied: every day5. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 2.6 hours. It is not a measured level or a suggested dose.

5

What somatropin products contain

The Humatrope label gives cartridge contents in both units, "6 mg (18 IU), 12 mg (36 IU), or 24 mg (72 IU) of somatropin", which is 3 IU for each 1 mg by division; its pharmacokinetic section gives a subcutaneous dose of "0.1 mg/kg (0.27 IU/kg)", which is 2.7 IU for each 1 mg.2 The Genotropin label states its strengths in milligrams: after reconstitution the 5 mg cartridge has a final concentration of 5 mg/mL and the 12 mg cartridge 12 mg/mL.5

Strength converter

Genotropin 5 mg cartridge, after reconstitution: 5 mg per mL5

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

6

Human studies

Each source's result is stated for its own group of people.

Table 6.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Salomon and colleagues, 19896Double-blind, placebo-controlled24 adults with growth hormone deficiency0.07 U/kg daily subcutaneously, 6 monthsLean body mass +5.5 ± 1.1 kg and fat mass -5.7 ± 0.9 kg (both P<0.0001); neither changed significantly on placebo; no effect on body weight
Genotropin label, adult trials5Six randomized trials, 6-month double-blind phase172 adults with growth hormone deficiency (85 Genotropin, 87 placebo)0.04 mg/kg/week for the first month, then 0.08 mg/kg/week, daily subcutaneousLean body mass up, fat mass and waist circumference down; bone mineral density down at 6 months, at baseline by 12
Rudman and colleagues, 199011Treated group against untreated group21 healthy men aged 61 to 81About 0.03 mg/kg subcutaneously 3 times a week, 6 monthsLean body mass +8.8% and adipose tissue -14.4% (P under 0.05 each); no significant change in the untreated group
Blackman and colleagues, 200212Randomized, double-blind, placebo-controlled, 2 x 2 factorial57 women and 74 men aged 65 to 8830 µg/kg reduced to 20 µg/kg subcutaneously 3 times a week, 26 weeksMen: lean body mass +3.1 kg with GH, +0.1 kg with placebo; strength did not increase significantly except a marginally significant +13.5 kg with GH plus testosterone (P=0.05); maximum oxygen uptake up with GH (P=0.11) and with GH plus testosterone (P<0.001)
Takala and colleagues, 19997Two randomized, placebo-controlled trials247 Finnish and 285 other European adults in intensive careMean 0.10 ± 0.02 mg/kg daily, up to 21 daysIn-hospital mortality, growth hormone against placebo: 39% against 20% (Finland), 44% against 18% (multinational); P<0.001 in both; among survivors, longer stay in intensive care and in hospital and longer mechanical ventilation
Meinhardt and colleagues, 201013Randomized, placebo-controlled, 8 weeks plus 6-week washout96 recreationally trained athletes (63 men, 33 women)2 mg/day subcutaneously for 8 weeks, alone or with testosterone 250 mg/week intramuscularly in menLean body mass rose through extracellular water; sprint capacity +0.71 kJ (95% CI 0.1 to 1.3) in men and women combined, not maintained 6 weeks after stopping; other performance measures not significantly changed
Liu and colleagues, 200714Systematic review, 18 study populations220 healthy recipients, mean age 69Mean initial 14 µg/kg/day, mean 27 weeksFat mass -2.1 kg and lean body mass +2.1 kg; more edema, arthralgias, carpal tunnel syndrome and gynecomastia; somewhat more likely onset of diabetes mellitus and impaired fasting glucose; weight, bone density and other serum lipid levels did not change significantly
Liu and colleagues, 20088Systematic review, 27 study samples303 healthy recipients, mean age 27Mean 36 µg/kg/day, mean 20 days in studies of more than 1 dayLean body mass +2.1 kg; strength and exercise capacity did not seem to improve; lactate during exercise statistically significantly higher in 2 of 3 studies; more edema and fatigue
Hermansen and colleagues, 20179Meta-analysis, 11 placebo-controlled studies254 healthy young subjectsNot stated in the recordLean body mass up and fat mass down (both p<0.01); exercising glycerol (p=0.01) and free fatty acids (p<0.01) up; anaerobic exercise capacity up (p<0.01) in the only study which investigated this; strength (p=0.36) and maximum oxygen uptake (p=0.89) not improved over weeks to months

Deeper analysis: adult growth hormone deficiency trials

Salomon, Cuneo, Hesp and Sönksen of Guy's and St Thomas' in London reported in the New England Journal of Medicine in 1989 a six-month trial in 24 adults with growth hormone deficiency, most acquired in adulthood after treatment for pituitary tumors.6 Basal metabolic rate rose significantly, and fasting plasma cholesterol was lower than on placebo (P under 0.05) while triglycerides were similar in the two groups.6 The authors conclude that growth hormone has a role in regulating body composition in adults, "probably through its anabolic and lipolytic actions", and the record states no funder, author tie or limitation.6 The Genotropin label is the manufacturer's, Pharmacia & Upjohn Company LLC, a subsidiary of Pfizer Inc., and reports its six trials together.5 The Endocrine Society's 2011 guideline, led by Molitch of Northwestern University, states that "GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD"; its record gives no funder or disclosure.15 The guideline also states that stimulation testing is usually required unless there is a proven genetic or structural lesion persistent from childhood, that "The risks associated with GH treatment are low" and that dosing regimens are to be individualized.15

Deeper analysis: Rudman and colleagues, men over 60

Rudman and colleagues of the Medical College of Wisconsin reported in the New England Journal of Medicine in 1990 a six-month treatment period that followed a six-month baseline period in 21 healthy men aged 61 to 81 whose plasma IGF-I was under 350 U per liter.11 Lumbar vertebral bone density rose 1.6% (P under 0.05), with no significant change in the bone density of the radius or proximal femur.11 The authors conclude that "Diminished secretion of growth hormone is responsible in part for the decrease of lean body mass"; the comparison group received no treatment, and the record mentions no placebo.11 The record lists grant support as BHP HRSA HHS and states no adverse events, limitations or author ties.11

Deeper analysis: Blackman and colleagues, healthy older women and men

Blackman, Harman and colleagues, working from Johns Hopkins University School of Medicine, reported in JAMA in 2002 a 26-week trial in 131 healthy people aged 65 to 88, randomized to growth hormone, sex steroids, both, or double placebo.12 In women, lean body mass rose 1.0 kg with growth hormone (P=0.001) against 0.4 kg with placebo, and strength and cardiovascular endurance did not change significantly.12 In men, strength "did not increase significantly except for a marginally significant increase of 13.5 kg with GH + testosterone (P =.05)", and maximum oxygen uptake declined by 1.2 mL/min/kg with placebo but increased with growth hormone (P=0.11) and with growth hormone plus testosterone (P<0.001), only the second of which is below P=0.05.12 Edema affected 39% of women on growth hormone against 0%, carpal tunnel symptoms 32% of men on growth hormone plus testosterone against 0%, and arthralgias 41% of men on growth hormone against 0%.12 Diabetes or glucose intolerance occurred in 18 growth hormone-treated men against 7 not receiving it (P=0.006).12 The authors cite frequent adverse effects, "importantly, diabetes and glucose intolerance", in a conclusion that confines growth hormone interventions in the elderly to controlled studies; the record lists grants from NCRR NIH HHS and NIA NIH HHS and gives no author ties or discontinuations.12

Deeper analysis: Meinhardt and colleagues, recreational athletes

Meinhardt, Nelson, Ho and colleagues of the Garvan Institute of Medical Research and St Vincent's Hospital in Sydney reported in the Annals of Internal Medicine in 2010 an 8-week randomized trial in 96 recreationally trained athletes.13 Growth hormone "significantly reduced fat mass, increased lean body mass through an increase in extracellular water, and increased body cell mass in men when coadministered with testosterone".13 Sprint capacity rose by 0.71 kJ (95% CI 0.1 to 1.3; relative increase 3.9%) in men and women combined and by 1.7 kJ (95% CI 0.5 to 3.0; relative increase 8.3%) in men also given testosterone, and the rise "was not maintained 6 weeks after discontinuation".13 The authors' stated limitations are that "Growth hormone dosage may have been lower than that used covertly by competitive athletes", that "The athletic significance of the observed improvements in sprint capacity is unclear", and that the study "was too small to draw conclusions about safety".13 The primary funding source was the World Anti-Doping Agency, and the record lists no author ties.13

Deeper analysis: Takala and colleagues, critically ill adults

Takala, Ruokonen, Webster and colleagues, with Kuopio University Hospital in Finland, reported in the New England Journal of Medicine in 1999 two parallel trials in adults who had been in intensive care for 5 to 7 days after cardiac surgery, abdominal surgery, multiple trauma or acute respiratory failure.7 The relative risk of death on growth hormone was 1.9 (95% CI 1.3 to 2.9) in the Finnish trial and 2.4 (95% CI 1.6 to 3.5) in the multinational trial.7 Among survivors, "the length of stay in intensive care and in the hospital and the duration of mechanical ventilation were prolonged in the growth hormone group".7 The authors conclude that "In patients with prolonged critical illness, high doses of growth hormone are associated with increased morbidity and mortality".7 The record lists no funder, author tie or limitation.7 The Genotropin label describes two such trials in non-growth hormone deficient adults (n=522), with mortality of 42% against 19% at 5.3 to 8 mg/day.5

Deeper analysis: reviews in healthy people

Liu, Hoffman and colleagues of Stanford University concluded in 2007 that in healthy older adults growth hormone "cannot be recommended as an antiaging therapy"; the record lists grants as NIA NIH HHS and AHRQ HHS, and their limitations include that "Most included studies had small sample sizes".14 Their 2008 review of athletic performance states that "Claims that growth hormone enhances physical performance are not supported by the scientific literature" and that growth hormone "may worsen exercise capacity and increase adverse events", with lactate levels during exercise "statistically significantly higher in 2 of 3 studies that evaluated this outcome"; the limitations are that "Few studies evaluated athletic performance" and that protocols "may not reflect real-world doses and regimens".8 Hermansen and colleagues of Aarhus University Hospital reported their meta-analysis of 11 placebo-controlled studies in 2017; their record names no funder, limitations or author ties.9

7

Doses reported in studies and on labels

The table gives label and trial doses, each for its own group and route; the other trials' doses are in the Human studies table.

Table 7.1Doses reported in studies and on labels4 rows
SourcePeopleDose reportedLengthRoute and note
Genotropin label, adult dosing section5Adults with growth hormone deficiencyStarting dose of approximately 0.2 mg/day (range 0.15 to 0.30 mg/day), or not more than 0.04 mg/kg/week at the start and not more than 0.08 mg/kg/week laterIncreases every 1 to 2 months or at 4 to 8 week intervalsSubcutaneous; the label states that maintenance dosages vary considerably from person to person
Salomon and colleagues, 1989624 adults with growth hormone deficiency0.07 U/kg daily6 monthsSubcutaneous at bedtime
Blackman and colleagues, 20021265 healthy adults aged 65 to 88 given growth hormone30 µg/kg, reduced to 20 µg/kg, 3 times a week26 weeksSubcutaneous; with or without sex steroids
Meinhardt and colleagues, 20101396 recreationally trained athletes (63 men, 33 women)2 mg/day (men and women)8 weeksSubcutaneous; men also given testosterone 250 mg/week intramuscularly in some groups

The app lists a typical dose of 1 to 6 IU a day, which is about 0.33 to 2 mg a day at the 3 IU per mg of the Humatrope cartridge strengths, or about 0.37 to 2.2 mg a day at the 2.7 IU per mg implied by that label's pharmacokinetic dose.2 None of the sources read gives that range as a dose; Meinhardt and colleagues gave 2 mg/day for 8 weeks.13

In clinical trials of Genotropin in 1,145 adults with growth hormone deficiency, the label states that "the majority of the adverse events consisted of mild to moderate symptoms of fluid retention", reported early and tending "to be transient and/or responsive to dosage reduction".5 In the first 6 months, peripheral swelling was reported by 17.5% on Genotropin (n=573) against 5.1% on placebo (n=572), arthralgia by 17.3% against 4.2%, pain in the extremities by 14.7% against 5.9%, peripheral edema by 10.8% against 2.6% and paresthesia by 9.6% against 1.9%.5 Upper respiratory infection was reported by 15.5% against 14.5%, headache by 9.9% against 7.7%, stiffness of the extremities by 7.9% against 1.6%, fatigue by 5.8% against 3.8% and myalgia by 4.9% against 1.6%.5 In post-trial extension studies diabetes mellitus developed in 12 of 3,031 patients (0.4%), all with predisposing factors, and 61 (2%) developed symptoms of carpal tunnel syndrome, which lessened after dosage reduction or treatment interruption (52) or surgery (9).5

The label's warnings include an increased risk of a second neoplasm, most commonly intracranial tumors and in particular meningiomas, in childhood cancer survivors treated with radiation to the brain or head for a first neoplasm; for adults it states that "it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence".5 It also states that "previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment".5

In healthy older adults, Liu and colleagues' 2007 review reported more soft tissue edema, arthralgias, carpal tunnel syndrome and gynecomastia and a somewhat higher likelihood of the onset of diabetes mellitus and impaired fasting glucose, and in healthy young adults their 2008 review reported more soft tissue edema and fatigue.14,8

9

Bloodwork and markers

The app lists IGF-1, blood glucose and insulin as the markers for somatropin. The Genotropin label says adult doses are adjusted "based on the clinical response and serum insulin-like growth factor I (IGF-I) concentrations".5 It states that "Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses in susceptible patients", and that in patients with growth hormone deficiency "central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment".5

10

Regulatory and anti-doping status

The Genotropin label lists contraindications that include treatment with pharmacologic amounts of somatropin in acute critical illness (after open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure), active malignancy, hypersensitivity to somatropin or excipients, active proliferative or severe non-proliferative diabetic retinopathy, and, in children, closed epiphyses.5

In the United States, 21 U.S.C. 333(e)(1) provides, except as provided in paragraph (2), that "whoever knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition", where such use has been authorized under section 355 and is pursuant to the order of a physician, "is guilty of an offense punishable by not more than 5 years in prison, such fines as are authorized by title 18, or both".16 Paragraph (2) provides "not more than 10 years imprisonment" where the offense involves an individual under 18 years of age, and paragraph (3) that a conviction "shall be considered a felony violation of the Controlled Substances Act" for the purposes of forfeiture.16 The statute defines human growth hormone as "somatrem, somatropin, or an analogue of either of them".16

The World Anti-Doping Agency's 2026 Prohibited List names "Growth hormone (GH), its analogues and fragments" in section S2.2.3, and section S2 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".17

11

Storage and handling

For the 5 mg and 12 mg single-patient-use cartridges, the Genotropin label states "Store GENOTROPIN lyophilized powder under refrigeration at 36°F to 46°F (2°C to 8°C) until the expiration date", in the package to protect from light, without freezing.5 After reconstitution the label states that the pen with the cartridge is kept under refrigeration "for up to 28 days".5

The Genotropin label states that its safety and effectiveness in patients aged 65 and over have not been evaluated in clinical studies, and the Humatrope label that its pharmacokinetics have not been studied in patients over 65.5,2 The Liu reviews and Meinhardt and colleagues state that few studies evaluated athletic performance, that most studies in healthy older adults were small, and that the athlete trial was too small for conclusions about safety.8,14,13 The five labels read are US labels, and these sources do not describe somatropin's status under other countries' rules. The app's duration of about 12 hours and typical dose of 1 to 6 IU a day are not stated in any of the sources read; the closest label figures are the IGF-1 time courses in the pharmacokinetics table.

What is the half-life of HGH?

The half-life of somatropin after subcutaneous injection is 2.0 hours (Norditropin label), 2.3 hours (Zomacton), 2.5 to 2.8 hours (Omnitrope) and 3.8 hours (Humatrope) in healthy adults, and 3.0 hours (Genotropin) in adults with growth hormone deficiency.1,3,4,2,5 The app lists about 2.6 hours.

What is the bioavailability of subcutaneous HGH?

The Humatrope label gives an absolute bioavailability of 75% after subcutaneous administration, the Genotropin label approximately 80% in adults with growth hormone deficiency and the Zomacton label approximately 70%.2,5,3 The app lists 75%, and the Norditropin label states its bioavailability "is currently not known".1

Is HGH banned by WADA?

Yes, the World Anti-Doping Agency's 2026 Prohibited List names growth hormone and its analogues and fragments in section S2.2.3.17 Section S2 is prohibited at all times, in and out of competition.17

Is it illegal to distribute HGH in the United States?

Under 21 U.S.C. 333(e)(1), except as provided in paragraph (2), knowingly distributing, or possessing with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition authorized under section 355 and pursuant to a physician's order is an offense punishable by not more than 5 years in prison, such fines as are authorized by title 18, or both; paragraph (2) provides not more than 10 years where the offense involves an individual under 18 years of age.16

How many IU are in 1 mg of HGH?

The Humatrope label's cartridge strengths of 6 mg (18 IU), 12 mg (36 IU) and 24 mg (72 IU) work out to 3 IU per mg by division, and the same label's pharmacokinetic dose of 0.1 mg/kg (0.27 IU/kg) to 2.7 IU per mg.2

What side effects does HGH cause?

In the Genotropin label's trials in 1,145 adults with growth hormone deficiency, "the majority of the adverse events consisted of mild to moderate symptoms of fluid retention", such as peripheral swelling in 17.5% on Genotropin against 5.1% on placebo in the first 6 months.5

Does growth hormone build muscle or strength?

In healthy young adults, Liu and colleagues' 2008 review reported lean body mass up by 2.1 kg while "strength and exercise capacity did not seem to improve".8 Hermansen and colleagues' 2017 analysis reported no improvement in muscle strength over weeks to months (p=0.36), and that growth hormone "significantly increased anaerobic exercise capacity (p<0.01) in the only study which investigated this".9 Meinhardt and colleagues reported sprint capacity up by 0.71 kJ in men and women combined, which "was not maintained 6 weeks after discontinuation".13

15

References

  1. Novo Nordisk. Norditropin (somatropin) injection, solution, prescribing information. DailyMed, label effective 7 July 2025. DailyMed label (Norditropin)
  2. Eli Lilly and Company. Humatrope (somatropin) kit, prescribing information. DailyMed, label effective 20 August 2026. DailyMed label (Humatrope)
  3. Ferring Pharmaceuticals Inc. Zomacton (somatropin) kit, prescribing information. DailyMed, label effective 20 April 2026. DailyMed label (Zomacton)
  4. Sandoz Inc. Omnitrope (somatropin) injection, solution and kit, prescribing information. DailyMed, label effective 10 July 2025. DailyMed label (Omnitrope)
  5. Pfizer Laboratories Div Pfizer Inc. Genotropin (somatropin) for injection, prescribing information. DailyMed, label effective 4 August 2026. DailyMed label (Genotropin)
  6. Salomon F, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989. PMID 2687691
  7. Takala J, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999. PMID 10477776
  8. Liu H, et al. Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008. PMID 18347346
  9. Hermansen K, et al. Impact of GH administration on athletic performance in healthy young adults: a systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res 2017. PMID 28514721
  10. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010. PMID 20664532
  11. Rudman D, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990. PMID 2355952
  12. Blackman MR, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002. PMID 12425705
  13. Meinhardt U, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann Intern Med 2010. PMID 20439575
  14. Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007. PMID 17227934
  15. Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011. PMID 21602453
  16. 21 U.S. Code section 333, Penalties, subsection (e) Prohibited distribution of human growth hormone. Legal Information Institute, Cornell Law School. 21 U.S.C. 333
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026